MIRAPEXIN 2.62 mg prolonged-release tablets

ATC Code
MIRAPEXIN 2.62 mg prolonged-release tablets

Boehringer Ingelheim International GmbH

Pharmacological group Dopaminergic agents


All to know

Authorisation holder

Boehringer Ingelheim International GmbH

What is it and how is it used?

MIRAPEXIN belongs to a group of medicines known as dopamine agonists, which stimulate dopamine receptors in the brain. Stimulation of the dopamine receptors triggers nerve impulses in the brain that help to control body movements.

MIRAPEXIN is used to treat the symptoms of primary Parkinson?s disease. It can be used alone or in combination with levodopa (another medicine for Parkinson?s disease).


What do you have to consider before using it?

Do not take MIRAPEXIN

  • if you are allergic (hypersensitive) to pramipexole or to any of the other ingredients of the tablets (see Section 6, ?Further information?).

Take special care with MIRAPEXIN

Tell your doctor if you have (had) or develop any medical conditions or symptoms, especially any of the following:

  • Kidney disease.
  • Hallucinations (seeing, hearing or feeling things that are not there). Most hallucinations are visual.
  • Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs). If you have advanced Parkinson?s disease and are also taking levodopa, you might develop dyskinesia during the up-titration of MIRAPEXIN.
  • Sleepiness and episodes of suddenly falling asleep.
  • Behavioural changes (e.g. pathological gambling, compulsive shopping), increased libido (e.g. increased sexual desire), binge eating.
  • Psychosis (e.g. comparable with symptoms of schizophrenia).
  • Vision impairment. You should have regular eye examinations during treatment with MIRAPEXIN.
  • Severe heart or blood vessels disease. You will need to have your blood pressure checked regularly, especially at the beginning of treatment. This is to avoid postural hypotension (a fall in blood pressure on standing up).
Children and adolescents

MIRAPEXIN is not recommended for use in children or adolescents under 18 years.

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines, herbal remedies, health foods or supplements that you have obtained without a prescription.

You should avoid taking MIRAPEXIN together with antipsychotic medicines.

Take care if you are taking the following medicines:

  • cimetidine (to treat excess stomach acid and stomach ulcers);
  • amantadine (which can be used to treat Parkinson?s disease);
  • mexiletine (to treat irregular heartbeats, a condition known as ventricular arrhythmia);
  • zidovudine (which can be used to treat the acquired immune deficiency syndrome (AIDS), a disease of the human immune system);
  • cisplatin (to treat various types of cancers);
  • quinine (which can be used for the prevention of painful night-time leg cramps and for the treatment of a type of malaria known as falciparum malaria (malignant malaria));
  • procainamide (to treat irregular heart beat).

If you are taking levodopa, the dose of levodopa is recommended to be reduced when you start treatment with MIRAPEXIN.

Take care if you are using any medicines that calm you down (have a sedative effect) or if you are drinking alcohol. In these cases MIRAPEXIN may affect your ability to drive and operate machinery.

Taking MIRAPEXIN with food and drink

You should be cautious while drinking alcohol during treatment with MIRAPEXIN. MIRAPEXIN can be taken with or without food.

Pregnancy and breast-feeding

Tell your doctor if you are pregnant, think you might be pregnant or if you intend to become pregnant. Your doctor will then discuss with you if you should continue to take MIRAPEXIN.

The effect of MIRAPEXIN on the unborn child is not known. Therefore, do not take MIRAPEXIN if you are pregnant unless your doctor tells you to do so.

MIRAPEXIN should not be used during breast-feeding. MIRAPEXIN can reduce the production of breast milk. Also, it can pass into the breast milk and can reach your baby. If use of MIRAPEXIN is unavoidable, breast-feeding should be stopped.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines

MIRAPEXIN can cause hallucinations (seeing, hearing or feeling things that are not there). If affected, do not drive or use machines.

MIRAPEXIN has been associated with sleepiness and episodes of suddenly falling asleep, particularly in patients with Parkinson?s disease. If you experience these side effects, you must not drive or operate machinery. You should tell your doctor if this occurs.

How is it used?

Always take MIRAPEXIN exactly as your doctor has told you. The doctor will advise you on the right dosing.

Take MIRAPEXIN prolonged-release tablets only once a day and each day at about the same time.

You can take MIRAPEXIN with or without food. Swallow the tablets whole with water.

Do not chew, divide or crush the prolonged-release tablets. If you do, there is a danger you could overdose, because the medicine may be released into your body too quickly.

During the first week, the usual daily dose is 0.26 mg pramipexole. The dose will be increased every 5-7 days as directed by your doctor until your symptoms are controlled (maintenance dose).

Ascending dose schedule of MIRAPEXIN prolonged-release tablets Week Daily dose mg Number of tablets 1 0.26 One MIRAPEXIN 0.26 mg prolonged-release tablet. 2 0.52 One MIRAPEXIN 0.52 mg prolonged-release tablet, OR two MIRAPEXIN 0.26 mg prolonged-release tablets. 3 1.05 One MIRAPEXIN 1.05 mg prolonged-release tablet, OR two MIRAPEXIN 0.52 mg prolonged-release tablets, OR four MIRAPEXIN 0.26 mg prolonged-release tablets.

The usual maintenance dose is 1.05 mg per day. However, your dose may have to be increased even further. If necessary, your doctor may increase your dose up to a maximum of 3.15 mg of pramipexole a day. A lower maintenance dose of one MIRAPEXIN 0.26 mg prolonged-release tablet a day is also possible.

Patients with kidney disease

If you have kidney disease, your doctor may advise you to take the usual starting dose of 0.26 mg prolonged-release tablets only every other day for the first week. After that, your doctor may increase the dosing frequency to one 0.26 mg prolonged-release tablet every day. If a further dose increase is necessary, your doctor may adjust it in steps of 0.26 mg pramipexole.

If you have serious kidney problems, your doctor may need to switch you to a different pramipexole medicine. If during treatment your kidney problems get worse, you should contact your doctor as soon as possible.

If you are switching from MIRAPEXIN (immediate release) tablets

Your doctor will base your dose of MIRAPEXIN prolonged-release tablets on the dose of MIRAPEXIN (immediate release) tablets you were taking.

Take your MIRAPEXIN (immediate release) tablets as normal the day before you switch. Then take your MIRAPEXIN prolonged-release tablets next morning and do not take any more MIRAPEXIN (immediate release) tablets.

If you take more MIRAPEXIN than you should

If you accidentally take too many tablets,

  • Contact your doctor or nearest hospital casualty department immediately for advice.
  • You may experience vomiting, restlessness, or any of the side effects as described in chapter 4 ?Possible side effects?.

If you forget to take MIRAPEXIN

If you forget to take a dose of MIRAPEXIN, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
If you forget for more than 12 hours, simply take the next single dose at the usual time. Do not take a double dose to make up for a forgotten tablet dose.

If you stop taking MIRAPEXIN

Do not stop taking MIRAPEXIN without first talking to your doctor. If you have to stop taking this medicine, your doctor will reduce the dose gradually. This reduces the risk of worsening symptoms.

If you suffer from Parkinson?s disease you should not stop treatment with MIRAPEXIN abruptly. A sudden stop could cause you to develop a medical condition called neuroleptic malignant syndrome which may represent a major health risk. The symptoms include:

  • akinesia (loss of muscle movement),
  • rigid muscles,
  • fever,
  • unstable blood pressure,
  • tachycardia (increased heart rate),
  • confusion,
  • depressed level of consciousness (e.g. coma).

If you have any further questions on the use of this product, ask your doctor or pharmacist.

What are possible side effects?

Like all medicines, MIRAPEXIN can cause side effects, although not everybody gets them. Evaluation of these side effects is based on the following frequencies:

Very common affects more than 1 user in 10 Common affects 1 to 10 users in 100 Uncommon affects 1 to 10 users in 1,000 Rare affects 1 to 10 users in 10,000 Very rare affects less than 1 user in 10,000 Not known frequency cannot be estimated from the available data

You may experience the following side effects:

Very common:

  • Dyskinesia (e.g. abnormal, uncontrolled movements of the limbs)
  • Sleepiness
  • Dizziness
  • Nausea (sickness)

  • Urge to behave in an unusual way
  • Hallucinations (seeing, hearing or feeling things that are not there)
  • Confusion
  • Tiredness (fatigue)
  • Sleeplessness (insomnia)
  • Excess of fluid, usually in the legs (peripheral oedema)
  • Headache
  • Hypotension (low blood pressure)
  • Abnormal dreams
  • Constipation
  • Visual impairment
  • Vomiting (being sick)
  • Weight loss including decreased appetite

  • Paranoia (e.g. excessive fear for one?s own well-being)
  • Delusion
  • Excessive daytime sleepiness and suddenly falling asleep
  • Amnesia (memory disturbance)
  • Hyperkinesia (increased movements and inability to keep still)
  • Weight increase
  • Increased sexual desire (e.g. increased libido)
  • Allergic reactions (e.g. rash, itching, hypersensitivity)
  • Fainting
  • Pathological gambling, especially when taking high doses of MIRAPEXIN
  • Hypersexuality
  • Increased eating (binge eating, hyperphagia)
  • Restlessness
  • Compulsive shopping
  • Dyspnoea (difficulties to breathe)
  • Hiccups
  • Pneumonia (infection of the lungs)

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

How should it be stored?

Keep out of the reach and sight of children.

Do not take MIRAPEXIN after the expiry date which is stated on the pack. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture.
This medicinal product does not require any special temperature storage conditions.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Further information

What MIRAPEXIN contains
The active substance is pramipexole.

Each tablet contains 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, or 3.15 mg pramipexole as 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, or 4.5 mg pramipexole dihydrochloride monohydrate, respectively.

The other ingredients are hypromellose 2208, maize starch, carbomer 941, colloidal anhydrous silica, magnesium stearate.

What MIRAPEXIN looks like and contents of the pack

MIRAPEXIN 0.26 mg and 0.52 mg prolonged-release tablets are white to off-white, of round shape, and have bevelled edges.
MIRAPEXIN 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg prolonged-release tablets are white to off-white and of oval shape.

All tablets have the Boehringer Ingelheim company symbol embossed on one side and the codes P1, P2, P3, P12, P4, P13, or P5 on the other side, representing the tablet strengths 0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg, respectively.

All strengths of MIRAPEXIN are available in aluminium blister strips of 10 tablets per strip, in cartons containing 1, 3 or 10 blister strips (10, 30 or 100 prolonged-release tablets). Not all pack sizes may be marketed.

Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
D-55216 Ingelheim am Rhein

Boehringer Ingelheim Pharma GmbH & Co. KG
D-55216 Ingelheim am Rhein

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

BelgiëBelgiqueBelgien SCS Boehringer Ingelheim Comm.V TélTel 32 2 773 33 11 LuxembourgLuxemburg SCS Boehringer Ingelheim Comm.V TélTel 32 2 773 33 11

- 359 2 958 79 98 Magyarország Boehringer Ingelheim RCV GmbH Co KG Magyarországi Fióktelepe Tel. 36 1 299 8900

eská republika Boehringer Ingelheim spol. s r.o. Tel 420 234 655 111 Malta Boehringer Ingelheim Ltd. Tel 44 1344 424 600

Danmark Boehringer Ingelheim Danmark AS Tlf 45 39 15 88 88 Nederland Boehringer Ingelheim b.v. Tel 31 0 800 22 55 889

Norge Boehringer Ingelheim Norway KS Tlf 47 66 76 13 00 Deutschland BIOTHERAX biochemisch-pharmazeutische Gesellschaft mbH Tel 49 0 800 77 90 900

Österreich Boehringer Ingelheim RCV GmbH Co KG Tel 43 1 80 105-0 Eesti Boehringer Ingelheim RCV GmbH Co KG Eesti filiaal Tel 372 60 80 940

Boehringer Ingelheim Ellas A.E. T 30 2 10 89 06 300 Polska Boehringer Ingelheim Sp.zo.o. Tel. 48 22 699 0 699

España Boehringer Ingelheim España S.A. Tel 34 93 404 58 00 Portugal Boehringer Ingelheim, Lda. Tel 351 21 313 53 00

France Boehringer Ingelheim France S.A.S. Tél 33 3 26 50 45 33 România Boehringer Ingelheim RCV GmbH Co KG Viena - Sucursala Bucuresti Tel 40 21 302 2800

Ireland Boehringer Ingelheim Ireland Ltd. Tel 353 1 295 9620 Slovenija Boehringer Ingelheim RCV GmbH Co KG, Podrunica Ljubljana Tel 386 1 586 40 00

Ísland Vistor hf. Sími 354 535 7000 Slovenská republika Boehringer Ingelheim RCV GmbH Co KG, organizaná zloka Tel 421 2 5810 1211

Italia Boehringer Ingelheim Italia S.p.A. Tel 39 02 5355 1 SuomiFinland Boehringer Ingelheim Finland Ky PuhTel 358 10 3102 800

Boehringer Ingelheim Ellas A.E. T 30 2 10 89 06 300 Sverige Boehringer Ingelheim AB Tel 46 8 721 21 00

United Kingdom Boehringer Ingelheim Ltd. Tel 44 1344 424 600 Latvija Boehringer Ingelheim Pharma GmbH Prstvniecba Latvij Tel 371 67 240 068


Boehringer Ingelheim RCV GmbH & Co KG
Lietuvos filialas
Tel.: +370 37 473922

This leaflet was last approved in {MM/YYYY}.



Your personal medicine assistent


Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.

This website is certified by Health On the Net Foundation. Click to verify.